This edition of the Carnival of Biotechnology features commentary on regulatory problems and progress, international development, and failed commercialization strategies. Regulatory The Washington Post has a report from the Institute of Medicine claiming that the drug review system is broken, and calling for changes. The Patent Barista’s update the road to biogenerics, profiling recent bills [...]
BiotechBlog’s Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Network and Share
Also from thinkBiotech
Translator
